Consensus conference on the management of tumor lysis syndrome.
about
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancerUrate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancerPrevention and management of tumor lysis syndrome in adults with malignancyTumor lysis syndrome: new challenges and recent advances.A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.SIL-TAL1 rearrangement is related with poor outcome: a study from a Chinese institution.Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Tumor lysis and acute renal failure in Burkitt's lymphoma: A review on pathophysiology and management.Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel.Intensive care of the cancer patient: recent achievements and remaining challengesMethemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review.Rasburicase for the treatment of tumor lysis in hematological malignancies.Pharmacogenetics of allopurinol--making an old drug safer.Spontaneous acute tumour lysis syndrome in gastric adenocarcinoma: a case report and literature review.Effective Prevention and Management of Tumor Lysis Syndrome in Children With Cancer: The Important Contributions of Pediatric Oncology Nurses.Hemolytic anemia following rasburicase administration: a review of published reports.Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.Green Tea and Bone Marrow Transplantation: From Antioxidant Activity to Enzymatic and Multidrug-resistance Modulation.Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.Management of Hyperleukocytosis.Tumor lysis syndrome in the emergency department: challenges and solutions.Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.Hyperleukocytosis and leukostasis: management of a medical emergency.Tumor lysis syndrome developing intraoperatively.Spontaneous Tumour Lysis Syndrome in a Multiple MyelomaAcute respiratory distress syndrome associated with tumor lysis syndrome in a child with acute lymphoblastic leukemia.Spontaneous tumour lysis syndrome in a case of multiple myeloma - A rare occurrence.Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit.Tumor Lysis Syndrome in Patients with Hematological Malignancies.Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.[Metabolic disorders as paraneoplastic syndromes].Spontaneous tumour lysis syndrome secondary to the transformation of chronic myelomonocytic leukaemia into acute myeloid leukaemia.Renal involvement in chronic lymphocytic leukemiaManaging Tumor Lysis Syndrome in the Era of Novel Cancer Therapies
P2860
Q24194387-8DDA0A0E-7E0B-4A47-9EE6-0AFA3A82D0E0Q24234902-924194E3-992C-4F1A-A906-B2F2D2E6BE68Q27003152-A83BB59A-5A53-4DF7-8A3E-B982AD2AE7CBQ33595615-2D7E4D67-F8C9-408D-B780-1F01DE942E2EQ33947841-F48B373F-B3B8-400E-B6CA-F3BD3E11F2A6Q34989431-0C5834BB-EED9-43A7-8A3A-C6EA0FE854BCQ35182162-BE804E32-0D7A-4054-935E-D4220976AC22Q37354482-76F4094A-7712-48C4-AC6C-B02DB4C5CFACQ37740958-0724BA6A-1F92-48E3-A28E-B83C1BA69D38Q37788882-6246DDA0-21B2-46DE-9B03-4A805799CF8BQ37866341-D339D85E-2D4D-4ACA-A29F-564337339A99Q37903768-FC118B01-A7BC-43F1-ACEE-1B993A84658BQ37929882-3CB2DB05-D47A-4F31-9BB3-ACACF63D4CBCQ37970663-FBB16F92-9D0C-45C3-B15D-EE329F9C5369Q37978342-4D90507B-4EAE-4FB0-B8D5-F5B558CDBEE0Q38079190-B59E85D4-EF51-4E54-B4DB-16527A4EF32AQ38222140-AA05A546-0953-4B5A-841A-5DD405570269Q38306316-13DA71A4-71F0-4B33-8DF9-3066CBCFD29DQ38374705-9A82547A-E73B-4D54-869E-A6F743D4296BQ38414165-BD7EB19C-A6A7-44AA-ABFB-F0564D769FEBQ38517370-1451AA89-27DF-4FE5-8AF8-C740B106E0C4Q38656591-DC1D8321-2597-4377-BEDF-F78AB2E11B0FQ38714787-A0D0CFE3-4CEC-4953-AE85-DE54002D65A8Q38826321-1B603A08-8FCC-4F25-8DEB-5880DDAD2047Q38921102-9BB4D9A7-2653-42FA-9133-F0229438D714Q39038221-50DEB64B-A3DE-4866-AC0D-5AE5DFA12F2AQ39058639-306F16F8-AB60-410F-9915-B276E2FFEFF6Q39106986-CD250157-EDB8-40F7-AED9-7FE48F7025A2Q39305834-EC01650C-E8F8-4994-8881-29618E40937EQ39838875-CC1A87C0-63E5-47E7-B5C2-E2B0DB5C034CQ40156982-60E2FBE4-75ED-4A4A-B96A-05ECA5A0DD38Q46949121-6970AC4E-A9FA-4266-A16B-0C3B46FB865AQ47887134-6CCDAF44-FD91-485F-955D-D820F4533A2CQ49581415-49FC5D3F-FCA0-41EC-99EC-D399115877C3Q54889444-B0B9592D-F1A3-41AD-8B1B-1C5DBA4C48EAQ57053852-F2702E72-08AF-46BD-A4BF-053279459438Q58585587-9815917A-8842-4868-83DD-16C3AC618B54
P2860
Consensus conference on the management of tumor lysis syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Consensus conference on the management of tumor lysis syndrome.
@en
Consensus conference on the management of tumor lysis syndrome.
@nl
type
label
Consensus conference on the management of tumor lysis syndrome.
@en
Consensus conference on the management of tumor lysis syndrome.
@nl
prefLabel
Consensus conference on the management of tumor lysis syndrome.
@en
Consensus conference on the management of tumor lysis syndrome.
@nl
P2093
P50
P356
P1433
P1476
Consensus conference on the management of tumor lysis syndrome.
@en
P2093
Antonio Santoro
Enrica Morra
Giovanni Barosi
Giovanni Rosti
Monia Marchetti
Patrizia Tosi
Sante Tura
Vincenzo Liso
P304
P356
10.3324/HAEMATOL.13290
P577
2008-10-06T00:00:00Z